Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers

Volume: 78, Issue: 16, Pages: 4642 - 4657
Published: Aug 14, 2018
Abstract
Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated and anaplastic thyroid cancers (Tpo-Cre/HrasG12V/p53flox/flox) with the FTI tipifarnib. Treatment caused sustained tumor regression and increased survival; however, early and late resistance was observed. Adaptive...
Paper Details
Title
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Published Date
Aug 14, 2018
Volume
78
Issue
16
Pages
4642 - 4657
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.